# Gain Therapeutics (GANX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GANX
## Company Profile
- Ticker: GANX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Switzerland
- Tags: CNS
## Stock Data
- Close: 2.12 USD
- Market cap: 78056889.54 USD
- Last updated: 2026-08-12
## Business Overview
### Allosteric Small-Molecule Platform
Gain Therapeutics uses its Magellan discovery platform to identify allosteric small molecules that restore the function of disease-associated proteins. Its lead efforts focus on neurodegenerative disorders.
### GT-02287
GT-02287 is an oral, brain-penetrant modulator of glucocerebrosidase being developed for Parkinson's disease with or without a GBA1 mutation. The candidate is intended to correct lysosomal dysfunction and potentially modify disease biology.
### Earlier Discovery Programs
The company's preclinical pipeline includes GT-04686 and related GCase modulators identified through the same structure-guided platform, providing follow-on opportunities in neurodegeneration.
## Why The Stock Is Moving

Following the latest company update, “Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update”, GANX closed up 16.4% at $2.06 on Aug 11, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Completion of the nine-month Phase 1b extension study of GT-02287 in October 2026.

## Recent News
- 2026-08-11 11:00 EST — [Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update](https://biopharmsignal.com/news/GANX/gain-therapeutics-reports-financial-results-for-second-quarter-2026-and-provides-3df2a449) — Source: Gain Therapeutics
- 2026-07-16 11:00 EST — [Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update](https://biopharmsignal.com/news/GANX/gain-therapeutics-ceo-gene-mack-issues-letter-to-shareholders-and-provides-opera-8b796693) — Source: Gain Therapeutics
- 2026-06-29 20:05 EST — [Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease](https://biopharmsignal.com/news/GANX/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt-02287-into-phase-2-11cfdeaf) — Source: Gain Therapeutics
- 2026-06-10 11:00 EST — [Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit](https://biopharmsignal.com/news/GANX/gain-therapeutics-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-exp-b322982c) — Source: Gain Therapeutics
- 2026-05-26 12:00 EST — [Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026](https://biopharmsignal.com/news/GANX/gain-therapeutics-presents-positive-interim-data-from-phase-1b-clinical-study-of-7715a5b9) — Source: Gain Therapeutics